Inotiv, Inc. acquired genetic toxicology assets from Sigma-Aldrich Corporation.
July 11, 2021
Share
Inotiv, Inc. (NasdaqCM:NOTV) acquired genetic toxicology assets from Sigma-Aldrich Corporation on July 12, 2021. Under the transaction, Inotiv acquired key genetic toxicology assets from MilliporeSigma's BioReliance® portfolio, including standard operating procedures, stock cultures, historic control data and client list. The transaction consists of a sales-based royalty agreement and does not require upfront funding from Inotiv. Inotiv will also offer employment to certain MilliporeSigma employees. As part of the arrangement, Gopala Krishna, has joined Inotiv as Senior Vice President, Genetic Toxicology, to lead the Company’s genetic toxicology service offering.
Inotiv, Inc. (NasdaqCM:NOTV) completed the acquisition of genetic toxicology assets from Sigma-Aldrich Corporation on July 12, 2021.
Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
INOTIV, INC. 
